Cenexi integration delays
Integration of Cenexi may face operational challenges, delaying synergy realization and margin improvement.
medium · management_commentaryGland Pharma Limited — Q1 FY24
Gland Pharma reported consolidated revenue of INR 1,209 crore for Q1 FY24, up 41% YoY, driven by the Cenexi acquisition (37% contribution) and 4% base business growth.
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
U.S. pricing pressure from Chinese competitors
Aggressive pricing by Chinese players in injectables could pressure margins, though management sees recent stabilization.
medium · analyst_questionDependence on enoxaparin recovery
Enoxaparin sales recovery is critical for U.S. growth; any further delays could impact revenue.
medium · analyst_questionCenexi summer shutdown impact
Annual four-week summer shutdown at Cenexi may temporarily affect revenue and margins in Q2.
low · management_commentary